Search
Metastatic Cancer Clinical Trials
A listing of 63 Metastatic Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
61 - 63 of 63
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Metastatic Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
There are currently 63 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Metastatic Cancer participants are California, Ohio, Michigan and Illinois.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Studying an Investigational Virus Vaccine
Recruiting
The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.
Conditions:
Healthy
Interested in vaccine studies
All Conditions
Preventative Trials
Featured Trial
Evaluating an Investigational Treatment for Hidradenitis Suppurativa
Recruiting
The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.
Conditions:
All Conditions
Hidradenitis suppurativa (Skin disorder)
Dermatology
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
Recruiting
This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OR2805 administered as a monotherapy and in combination with anti-cancer agents in subjects with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/31/2023
Locations: HonorHealth Research Institute, Scottsdale, Arizona +2 locations
Conditions: Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Leiomyosarcoma, Liposarcoma
Efficacy of Point Of Service Testing in MBC
Recruiting
This study will assess the efficacy of an innovative point of service cancer genetics counseling delivery model for metastatic breast cancer (MBC) patients whom have received a referral for hereditary cancer genetic counseling and testing.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/21/2023
Locations: The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas
Conditions: Metastatic Cancer, Breast Cancer
A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Recruiting
This is a Phase 1/1b open-label, dose-escalation, and cohort expansion study with BID (tablet) oral dose of MPT-0118 in subjects with advanced or metastatic refractory solid tumors.
The study will be conducted in 3 parts:
Part A: MPT-0118 dose-escalation
Part B: MPT-0118 dose-escalation in combination with pembrolizumab
Part C: Cohort expansion of MPT-0118 in combination with pembrolizumab
Gender:
All
Ages:
18 years and above
Trial Updated:
09/15/2021
Locations: St. John's Cancer Center, Santa Monica, California +4 locations
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Refractory Cancer
61 - 63 of 63